However, data on the efficacy and safety of anti-Programmed cell Death-1 (PD-1)/PD-1 Ligand 1 (PD-L1) antibodies for NSCLC with PS 2 are much more limited than for cytotoxic chemotherapy, with only a few reports of interventional studies, let alone randomized trials. Here, PDCD1 is linked to non-small cell lung carcinoma.